UNSPSC 51373419: Calcium iodide/codeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373419 Calcium iodide/codeine is a Commodity code that in practice covers emergency medical supplies and pharmaceutical products, though the recent state and local opportunities tagged to it diverge significantly from the nominal scope. Seminole County, Florida is procuring naloxone and drug deactivation systems, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administers a statewide RFP for generic multi-source pharmaceuticals and over-the-counter products distributed across state and local facilities in Minnesota and Oregon. The actual work being solicited includes emergency opioid-reversal supplies, harm-reduction equipment, and broad-spectrum generic pharmaceutical distribution through authorized wholesaler networks. Issuing bodies range from individual county health departments to multistate cooperative purchasing vehicles administered by state procurement offices, reflecting the mixed sourcing patterns typical of public health supply chains.

Recent activity centers in Florida and the upper Midwest. Seminole County's IFB (due July 26, 2023, per the source) calls for annual delivery of 1,900 units of naloxone and 800 safe drug deactivation systems to the Seminole County Community Health Building with quarterly shipments and a two-year initial term plus one-year renewal option. MMCAP's RFP (posted January 20, 2026, questions due February 18, 2026, proposals due March 26, 2026) establishes contracts for generic pharmaceuticals and OTC products across multistate members, with awards effective July 1, 2026, requiring vendors to supply through three authorized wholesalers (Cencora, Cardinal Health 110/112, and Morris & Dickson) and comply with cGMP, DSCSA, and FDA requirements; evaluation emphasizes price competitiveness (75 percent weighting) and administrative compliance (5–10 percent each). Neither opportunity identifies explicit set-asides for disadvantaged enterprises, though both mandate standard workplace certification, insurance coverage, and federal compliance overlays.